PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of aaciBioMed CentralBiomed Central Web Sitesearchsubmit a manuscriptregisterthis articleAllergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology
 
Allergy Asthma Clin Immunol. 2017; 13: 17.
Published online 2017 April 4. doi:  10.1186/s13223-017-0190-0
PMCID: PMC5379704

Sputum cell counts to manage prednisone-dependent asthma: effects on FEV1 and eosinophilic exacerbations

Abstract

Background

Prednisone dependence in asthma is usually described based on clinical and spirometric characteristics. It is generally believed that these patients have frequent exacerbations and lose lung function rapidly because of uncontrolled airway eosinophilia.

Objectives

The objectives of this study are to report the effect on asthma exacerbations and the change in lung function over time in prednisone-dependent asthma when severe asthma is managed using a protocol that aims to maintain normal sputum cell counts.

Methods

A retrospective survey of patients prospectively assessed in a university tertiary care asthma clinic.

Results

52 patients (30 males, mean age 51 years, 64% non-atopic) were followed for a median period of 5.4 years (min–max: 0.2–35.2). Monitoring with the aim of keeping sputum eosinophils below 3% resulted in higher doses of corticosteroids (median daily dose of prednisone was 10 mg and for inhaled corticosteroids was 1500 μg of fluticasone equivalent) than at baseline and this was associated with predictable adverse effects. Despite the disease severity, 10 patients (19%) did not require LABA for symptom control. Most importantly, over the period of follow-up, there were only 0.3 eosinophilic exacerbations/patient/year. Overall, there was an increase in FEV1 over the period of follow-up (mean +84.6 ml/year) rather than an expected decline.

Conclusions

Monitoring of eosinophils in sputum enables to maintain symptom control and preserve FEV1 in patients with severe prednisone-dependent asthma.

Keywords: Severe asthma, Prednisone, Sputum cell counts, Eosinophils, FEV1, Exacerbations

Background

Asthma management guided by sputum cell counts has been shown to reduce eosinophilic exacerbations [1, 2] and is cost-effective [3]. This is particularly true for patients with moderate to severe asthma as most patients with mild asthma may not require a biomarker-guided treatment strategy [4]. However, it is not known if patients with the severest forms of asthma i.e. those that require daily prednisone would also benefit from a sputum-based management strategy. It is generally believed that these patients have frequent exacerbations, particularly those with persistent sputum eosinophilia [5] and that they lose lung function over time with each exacerbation [6]. These patients, although fortunately infrequent, consume the largest health care resources for asthma care [7]. They often have significant adverse effects from their doses of corticosteroids [8] and these are the patients who may benefit most with the advent of biologics that target the Th2 cytokine pathways [9].

The recent experience from the British Thoracic Society Severe Asthma program suggest that the clinical outcomes of patients with severe asthma are better if they are managed in specialized asthma centres than in general clinics [10]. A severe asthma clinic was set up at the Firestone clinic at St Joseph’s Healthcare in Hamilton, ON in the early 1970s where patients were looked after by a respiratory physician (FEH) who was supported by a research staff of two technologists and one clinical trainee who was often a respiratory physician. The two unique features of this clinic were the introduction of quantitative cell counts in sputum to adjust initial treatment requirements and secondly (and more importantly) accessibility to these measurements within 72 h of any worsening of asthma symptoms. The main objectives of this manuscript are to describe the effects of this strategy on FEV1 and on exacerbations in patients with prednisone-dependent asthma who were referred to this clinic.

Study design and methods

This was a retrospective descriptive chart review of patients with a physician-confirmed diagnosis of asthma (defined as episodic wheeze, chest tightness or shortness of breath and confirmed variable airflow obstruction of at least 12% and 200 ml improvement in FEV1 after inhaling 200 mcg of salbutamol or a PC20 methacholine of <8 mg/ml), and who were on a maintenance dose of at least 5 mg of prednisone daily for at least 6 months prior to the initial consultation, who were referred to a severe asthma clinic at the Firestone Institute in Hamilton, Ontario, between 1973 and 2008. Basic clinical and demographic data were documented. Pre-and post-bronchodilator reversibility were recorded according to the American Thoracic Society standards [11]. Airway responsiveness to methacholine was assessed by the tidal breathing method of Cockcroft et al. [12] if the FEV1 was >65% of predicted. Symptoms of cough, wheeze, chest tightness, dyspnea and sputum production were documented on a 7-point Likert scale (1 being worst and 7 being best). Tools to assess “asthma control” and “asthma-specific quality of life” were not available when the first patients were recruited into this program. Sputum was induced and processed according to the methods described by Pizzichini et al. [13].

Asthma was managed according to the protocol described by Jayaram et al. [1]. Briefly, the dose of inhaled corticosteroids or prednisone was increased to maintain sputum eosinophils less than 3% (or until free eosinophil granules were no longer present). If sputum total cell count was greater than 15 × 106/g and neutrophils greater than 65%, the patients were treated with a broad spectrum antibiotic (zithromycin or amoxicillin + clavulanic acid for 5–7 days). Most importantly, the dose of steroid was not increased. Long-acting bronchodilators (salmeterol or formoterol) were added to the inhaled steroids only after the bronchitic component was controlled and the patient continued to have shortness of breath or wheezing that required more than 2–4 puffs of short-acting bronchodilators daily. They were not added if spirometry did not show any worsening of airflow obstruction or if PC20 methacholine was greater than 8 mg/ml or had not worsened by more than one doubling dose. If the sputum eosinophil % was less than 1%, the dose of corticosteroids was reduced. Sputum was always rechecked with 6–8 weeks of any treatment change. Once the maintenance dose of steroid was identified, patients were left on this dose indefinitely and seen in follow-up on average twice a year at which time spirometry, sputum and blood counts, clinical asthma control and adverse effects of therapy were assessed by self-reported history. Methacholine airway responsiveness was also reassessed if patients reported an increase need for short-acting bronchodilators and the sputum cell counts were normal and if it was felt safe to perform the test (usually FEV1 > 65% predicted). Adherence to prescribed medications was continuously assessed by checking the pharmacy records every year.

If patients experienced any worsening of symptoms (increase in chest tightness or wheezing requiring at least four puffs of salbutamol daily or at night, increase in sputum production or change in colour to dark yellow or green) they were instructed to call our research office. Patients were brought to the clinic within 72 h for a clinical assessment, spirometry, and collection of either spontaneously expectorated or induced sputum. They were phoned back the same evening or the next morning with instructions to change their medication dosages. If patients had seen their family doctor and had received either antibiotics or prednisone without being seen at our clinic, this information was documented in the clinic chart. All the demographic and clinical information was meticulously extracted by a research assistant (AAR) and verified by a research technologist (MK) after obtaining approval from the Hospital Research Ethics Board.

Statistical analysis

Baseline demographic and clinical data were summarized using descriptive statistics. The rates of change of FEV1 (ml/year) were analyzed by multilevel linear regression using three time points (at baseline, time when sputum quantitative assay became normal and at the most recent assessment) for each gender and smoking status separately. As a first step, individual FEV1s were regressed against time to find rates of change (ml/year) for each patient. In the second step of multilevel linear regression, the rates of change (ml/year) for each patient (dependent variable) were regressed with age and height as the independent variables. The final rate of change of FEV1 in a specific group e.g. males, females, smokers and nonsmokers was computed using the mean age and height of the respective groups. The analyses were carried out using SPSS (version 16). Since we did not have a comparison group of patients with milder asthma or patients with severe asthma who were not monitored using sputum cell counts, we plotted the rates of decline of our cohort against the data published by Ulrik et al. [14] for patients with mild asthma. Paired data were compared by Student’s t test. P-value was considered significant if <0.05.

Results

The study included 52 (30 males and 22 females) patients. The baseline characteristics of all patients are tabulated in Table 1. The median time of follow up of all patients was 5.42 years (minimum 0.15, maximum 35.26).

Table 1
Baseline characteristics (n = 52)

Effect on sputum cell counts

Sputum eosinophil counts were normalized in all patients within a median period of 5 months (Table 2). This was associated with a trivial (but statistically significant) increase in sputum neutrophil % (Table 2; Fig. 1). The cell counts remained stable for the rest of the follow-up period.

Table 2
Sputum, blood counts and spirometry (mean, SD) values
Fig. 1
Sputum cell counts at first visit, when eosinophils are normalized, and current

Effect on FEV1

The rate of change of FEV1 from baseline value to the time point when sputum quantitative assay became normal was 1201.24 ml/year (95% CI 199.31 to 2202.7 ml/year) while the rate of change (decline) from the time sputum was normal to the time when the patient was last seen was a modest −14.9 (95% CI 53.4 to −83.2) ml/year. The overall (baseline to when last seen) rate of change of FEV1 was 84.63 (95% CI −44.6 to 213.8) ml/year. The corresponding values in males were 970.53 (95% CI 178.5 to 1762.4) ml/year, −28.36 (95% CI −18.1 to −38.6) ml/year and the overall rate of change was 113.99 (95% CI 70.6 to 157.4) ml/year and for females were 1515.85 (95% CI −701.1 to 3732.7) ml/year, 3.44 (95% CI −115.7 to 122.6) ml/year and the overall rate of change was 44.59 (95% CI −95.6 to 184.8) ml/year. There were however no statistically significant difference between males and females in their rates of change of FEV1. The rates of change of FEV1 for male smokers were : from baseline to when sputum was normal 1433.13 (95% CI 199.3 to 2666.9) ml/year, from when sputum was normal to when last seen 6.09 (95% CI −113.1 to 125.3) ml/year and overall 227.31 (95% CI −91.9 to 546.5) ml/year and for females smokers were: from baseline to when sputum was normal 663.8 (95% CI −332.4 to 1660.0) ml/year, from when sputum was normal to when last seen 21.54 (95% CI −310.1 to 353.1) ml/year and overall 82.58 (95% CI −306.6 to 471.8) ml/year. The corresponding values for male nonsmokers were: 171.48 (95% CI −78.0 to 420.9) ml/year, −87.86 (95% CI −218.7 to 43.02) ml/year and −81.73 (95% CI −190.5 to 27.1) ml/year and for female nonsmokers were: 2105.74 (95% CI −1801.4 to 6012.9) ml/year, −9.09 (95% CI −35.3 to 17.2) ml/year and 18.28 (95% CI −11.4 to 47.9) ml/year. There were no statistical differences in rates of change of FEV1 between the genders when smokers and nonsmokers were analysed separately.

Effect on exacerbations

Over the 2 years prior to attending our clinic, the patients had reported an average of 1.9 exacerbations/patient/year that had responded to prednisone. Since sputum was not examined during these exacerbations, we cannot confirm that these were eosinophilic, but we assume they were as patients reported improvement in their asthma symptoms within 48–72 h of therapy. This was reduced to 0.3 eosinophilic exacerbations/patient/year over the course of the follow-up period. The average time of resolution of individual exacerbations was 4 days. We did not have accurate records of “non-eosinophilic” or “neutrophilic” exacerbations before their initial visit to our clinic. During the course of the follow-up, the patients had 1.2 neutrophilic exacerbations/patient/year that were treated with antibiotics.

Effects related to corticosteroids

The median duration of the steroid optimization phase was 5 months (min–max 1–7 months). During this period, the median daily dose of prednisone was 10 mg (minimum 5 mg, maximum 35 mg) and the dose of inhaled corticosteroid was 1500 mcg of fluticasone equivalent. This dose was maintained for the duration of the follow-up period. Five patients required the dose of prednisone to be increased after the maintenance dose was established. Corticosteroids caused predictable adverse effects (Table 3) that were appropriately managed.

Table 3
Co-morbidities and adverse effects of prednisone

Effects related to LABA

At initial assessment, 22 patients were on LABA (15 on salmeterol, 7 on formoterol). Over the course of the follow-up period, 20 patients were also commenced on LABA. The median period to commencement of LABA was 2 years (minimum 2 months, maximum 4 years). 10 patients have not required LABA for symptom control as their asthma severity (and airflow obstruction) was largely driven by steroid-responsive luminal eosinophilic inflammation rather than by bronchodilator-responsive smooth muscle dysfunction.

Discussion

This retrospective study illustrates three important concepts. Firstly, when available, incorporation of timely measurements of sputum quantitative cytometry and airway hyperresponsiveness into routine clinical practice is feasible and effective in the management of severe prednisone-dependent patients with asthma. Secondly, this strategy can reduce exacerbations and preserve lung function albeit at the cost of adverse effects of glucocorticoids. Thirdly, recognition of the component of asthma that leads to severity can help to rationalize the inappropriate use of long-acting bronchodilators that are associated with asthma morbidity.

To our knowledge, this is the first study that reports the preservation of lung function in patients with severe asthma. Not only did we not observe the expected decline in FEV1 over time that has been reported in patients with “eosinophilic severe asthma” [5, 15], but there was a modest improvement over the period of observation suggesting that the current symptom-based guideline therapies underestimate the control of airway inflammation. We analysed longitudinal data using three time points i.e. when first seen, when sputum became normal and when a patient was last seen. The rate of change of FEV1 was positive when the rate was computed from the baseline value to the point when the airway inflammation (or the sputum quantitative assay) became normal (Fig. 2), whereas the rate of change of FEV1 thereafter, from the time sputum was normal to the time when the patient was last seen was a modest −14 ml/year which is clearly lesser than that reported in previous longitudinal asthma studies [6, 1518]. The overall improvement in FEV1 in this study is possibly driven by the fact that most patients had an improvement in lung function when sputum became normal after intensive anti-inflammatory therapy and that too within a short span of time resulting in high rates of improvement in FEV1 with time. Comparison with a matched group of patients at the Firestone clinic with similar severity of asthma who were managed based on symptoms only would have certainly added strength to the study. Unfortunately, such data were not available to us. However, it is extremely unlikely that treatment based on symptoms alone would give results similar to treatment using a sputum strategy [1].

Fig. 2
Mean FEV1 (with 95% CI) at three time points (when first seen, when sputum became normal, when last seen). Asterisk rates of decline are for the average age and height for the respective group

Figure 2 illustrates a comparison of rates of change of FEV1 between this study and that by Ulrik et al. We fully realize that these two studies are not entirely comparable given the differences such as patient population, management strategies, sampling strategies etc. [14]. However, most longitudinal asthma studies are population based observational reports. We selected the Ulrick study as this is one of the larger longitudinal asthma studies and employed a similar statistical analysis method to what we performed. Various factors such as gender, smoking, age of onset, atopy, sputum eosinophilia, presence of mucous hyper secretion and use of inhaled corticosteroids have been implicated as affecting the rate of change in FEV1 in asthmatics. However, methodological issues have led to wide variations in these observations resulting in a lot of heterogeneity in the reported rates of decline in FEV1. Rates of decrease of FEV1 have varied from 25.7 ml/year in severe asthma [15], 31.5 ml/year in asthmatic patients with frequent exacerbations vs 14.6 ml/year in those with infrequent exacerbations [6], 26.6 ml/year in occupational asthmatics who were exposed to low-molecular-weight sensitizers at work [16], 28.4–39.7 ml/year in adult nonsmoker asthmatic patients in the Busselton cohort [17], to 16.1–21.5 ml/year in asthmatic patients receiving inhaled corticosteroids [18]. In the current study, the rate of decline from when sputum was normal to when last seen is similar to the decline rate reported in asthmatics with infrequent exacerbations [6]. Interestingly, in our study there were no statistical differences in rates of change of FEV1 either between the genders (Fig. 3) or when smokers and nonsmokers were analysed (Figs. 4, ,5)5) separately. Regardless of the fact that it may not be apt to compare studies with dissimilar populations and methodologies, we were able to demonstrate, perhaps for the first time, a strategy that did not use biologics that could preserve lung function even when asthma is severe. Only the eosinophilic inflammatory component could be effectively targeted with corticosteroids. We did not have any effective or specific strategy (other than antibiotics) to treat neutrophilic bronchitis. We speculate that lung function could perhaps have been better preserved had broader strategies effective against non-T2 type inflammation as well been available for clinical use.

Fig. 3
Comparison of predicted (calculated) FEV1 vs time in years (Current Study vs Ulrik et al.). Dotted lines males, solid line females; predicted rates of decline and FEV1 for both studies are for the mean age (males 52.4 years, females 49.8 ...
Fig. 4
Predicted (calculated) FEV1 vs time in years for males (Baseline to last seen) showing no statistical difference between smokers and nonsmokers; dashed line all patients, solid line smokers, dash and dot line nonsmokers. Predicted ...
Fig. 5
Predicted (calculated) FEV1 vs time in years in females (Baseline to last seen) showing no statistical difference between smokers and nonsmokers; dashed line all patients, solid line smokers, dash and dot line nonsmokers. Predicted ...

A second important point that we would like to highlight in this report is that patients could be on high doses of corticosteroids and not necessarily require long-acting beta-agonists if the severity is driven by luminal inflammation rather than by smooth muscle dysfunction. This is not often appreciated in clinical practice nor is it emphasized in the guidelines. In our cohort, the use of long-acting beta-agonist could be delayed or withheld in a small proportion of severe asthmatics in whom there is the highest concern for their adverse effects [19]. This also questions the veracity of recommendations to consider anti-eosinophil biologics (such as mepolizumab or reslizumab) as steroid-sparing therapy only after adding long-acting bronchodilators [20] when long-acting beta-agonists do not have any proven anti-eosinophil activities [21]. It is reasonable to consider biologics in patients whose disease are truly driven by eosinophils (as identified by persistent sputum eosinophils and blood eosinophils) and who have adverse effects from high doses of corticosteroids independent of their need for long-acting bronchodilators.

The major limitation of our study is the retrospective nature of data collection that spans over 25 years, the absence of a comparator group, and the lack of precision in the definition of exacerbations prior to referral to our clinic. It is also plausible that some of the exacerbations may not have been reported to us during the period of follow up. We did not use any sophisticated method to assess compliance other than self reports and pharmacy logs.

Conclusion

In conclusion, we recommend monitoring of eosinophils in sputum in patients with severe prednisone-dependent asthma as this strategy enables to maintain symptom control, reduce exacerbations and preserve FEV1 in these patients. The test is not intrusive and is acceptable to most patients [22]. This study was performed before anti-IL5 monoclonal antibodies were available for clinical use but the results demonstrate that most patients would not require them for improving asthma control but they would be useful to avoid the adverse effects of corticosteroids. Our experience also provides ‘proof-of-principle’ that ‘remission’ [23] can be achieved even in severe asthma by judicious use of currently available therapy, albeit at the price of adverse effects of therapy.

Author’s contributions

PN and FEH conceived the idea. MK did most of the clinical assessments. AR extracted and compiled the data. AG performed the statistical analysis. PN wrote the manuscript, All authors, except FEH, have edited the final version. All authors (except FEH) read and approved the final manuscript.

Acknowledgements

Dr. Nair holds the Frederick E. HargreaveTeva Innovation Chair in Airway Diseases. We dedicate this manuscript to the memory of Prof. Frederick Hargreave.

Competing interests

PN is supported by the Frederick E. HargreaveTeva Innovation Chair in Airway Diseases. He has received consultancy fees from AstraZeneca, BoehringerIngelheim, Sanofi, Teva, Knopp, Theravance, and Roche; research support from GlaxoSmithKline, AstraZeneca, Sanofi, Roche, and Novartis; and lecture fees from Roche, AstraZeneca, and Novartis. Rest of the contributing authors do not have any competing interests to declare for this work.

Availability of data and materials

Please contact author for data requests.

Ethics approval and consent to participate

The study was approved by the Research Ethics Board of St Joseph’s hospital, Hamilton and all patients had provided consent to have their sputum cell counts and clinical data stored in a secure anonymized database.

Funding

The study was supported by the Canada Research Chair program.

Abbreviations

FEV1
forced expiratory volume in the first second
PC20
provocative concentration to cause a 20% drop in FEV1
LABA
long-acting beta-agonist
ICS
inhaled corticosteroid

Footnotes

Afia Aziz-Ur-Rehman and Angira Dasgupta contributed equally to this work

Contributor Information

Afia Aziz-Ur-Rehman, ac.oohay@ziza.aifA.

Angira Dasgupta, moc.liamg@atpugsadarigna.

Melanie Kjarsgaard, ac.seojts@agsrajkm.

Frederick E. Hargreave, ac.retsamcm@vaergrah.

Parameswaran Nair, Phone: 905-522-1155, ac.retsamcm@semarap.

References

1. Jayaram L, Pizzichini MM, Cook RJ, et al. Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. Eur Respir J. 2006;27:483–494. doi: 10.1183/09031936.06.00137704. [PubMed] [Cross Ref]
2. Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet. 2002;360:1715–1721. doi: 10.1016/S0140-6736(02)11679-5. [PubMed] [Cross Ref]
3. Dsilva L, Gafni A, Thabane L, et al. Cost analysis of monitoring asthma treatment using sputum cell counts. Can Respir J. 2008;15:370–374. doi: 10.1155/2008/946735. [PMC free article] [PubMed] [Cross Ref]
4. Nair P, Dasgupta A, Brightling CE, Chung KF. How to diagnose and phenotype asthma. Clin Chest Med. 2012;33:445–457. doi: 10.1016/j.ccm.2012.05.003. [PubMed] [Cross Ref]
5. Walsh CJ, Zaihra T, Benedetti A, et al. Exacerbation risk in severe asthma is stratified by inflammatory phenotype using longitudinal measures of sputum eosinophils. Clin Exp Allergy. 2016;46:1291–1302. doi: 10.1111/cea.12762. [PubMed] [Cross Ref]
6. Bai TR, Vonk JM, Postma DS, Boezen HM. Severe exacerbations predict excess lung function decline in asthma. Eur Respir J. 2007;30:452–456. doi: 10.1183/09031936.00165106. [PubMed] [Cross Ref]
7. O’Neill S, Sweeney J, Patterson CC, et al. The cost of treating severe refractory asthma in the UK: an economic analysis from the British Thoracic Society Difficult Asthma Registry. Thorax. 2015;70:376–378. doi: 10.1136/thoraxjnl-2013-204114. [PubMed] [Cross Ref]
8. Dalal AA, Duh MS, Gozalo L, et al. Dose–response relationship between long-term systemic corticosteroid use and related complications in patients with severe asthma. J Manag Care Spec Pharm. 2016;22:833–847. doi: 10.18553/jmcp.2016.22.7.833. [PubMed] [Cross Ref]
9. Dasgupta A, Neighbour H, Nair P. Targeted therapy of bronchitis in obstructive airway diseases. Pharmacol Ther. 2013;140:213–222. doi: 10.1016/j.pharmthera.2013.07.001. [PubMed] [Cross Ref]
10. Gibeon D, Heaney LG, Brightling CE, et al. Dedicated severe asthma services improve health-care use and quality of life. Chest. 2015;148:870–876. doi: 10.1378/chest.14-3056. [PubMed] [Cross Ref]
11. American thoracic Society Standardization of spirometry. 1994 update. Am Rev Respir Dis. 1995;1995(152):1107–1136. [PubMed]
12. Juniper EF, Cockcroft DW, Hargreave FE. Histamine and methacholine inhalation test: tidal breathing method, laboratory procedure and standardization. 2nd ed; 1994, p. 33–4.
13. Pizzichini E, Pizzichini MM, Efthimiadis A, Hargreave FE, Dolovich J. Measurement of inflammatory indices in induced sputum: effects of selection of sputum to minimize salivary contamination. Eur Respir J. 1996;9:1174–1180. doi: 10.1183/09031936.96.09061174. [PubMed] [Cross Ref]
14. Ulrik CS, Lange P. Decline of lung function in adults with bronchial asthma. Am J Respir Crit Care Med. 1994;150:629–634. doi: 10.1164/ajrccm.150.3.8087330. [PubMed] [Cross Ref]
15. Newby C, AgbetileJ Hargadon B, et al. Lung function decline and variable airway inflammatory pattern: longitudinal analysis of severe asthma. J Allergy Clin Immunol. 2014;134:287–294. doi: 10.1016/j.jaci.2014.04.005. [PubMed] [Cross Ref]
16. Anees W, Moore VC, Burge PS. FEV1 decline in occupational asthma. Thorax. 2006;61:751–755. doi: 10.1136/thx.2005.054080. [PMC free article] [PubMed] [Cross Ref]
17. James AL, Palmer LJ, Kicic E, Maxwell PS, Lagan SE, Ryan GF, et al. Decline in lung function in the Busselton Health Study: the effects of asthma and cigarette smoking. Am J Respir Crit Care Med. 2005;171:109–114. doi: 10.1164/rccm.200402-230OC. [PubMed] [Cross Ref]
18. Dijkstra A, Vonk JM, Jongepier H, Koppelman GH, Schouten JP, ten Hacken NH, et al. Lung function decline in asthma: association with inhaled corticosteroids, smoking and sex. Thorax. 2006;61:105–110. doi: 10.1136/thx.2004.039271. [PMC free article] [PubMed] [Cross Ref]
19. Rodrigo GJ, Castro-Rodrıguez JA. Safety of long-acting β agonists for the treatment of asthma: clearing the air. Thorax. 2012;67:342. doi: 10.1136/thx.2010.155648. [PubMed] [Cross Ref]
20. Nucala product monograph, http://ca.gsk.com/media/1209435/nucala.pdf. Accessed 25 Feb 2017.
21. Sindi A, Todd DC, Nair P. Anti-inflammatory effects of long-acting beta2-agonists in patients with asthma: a systematic review and meta-analysis. Chest. 2009;136:145–154. doi: 10.1378/chest.08-2149. [PubMed] [Cross Ref]
22. D’silva L, Neighbour H, Gafni A, Radford K, Hargreave F, Nair P. Quantitative sputum cell counts to monitor bronchitis: a qualitative study of physician and patient perspectives. Can Respir J. 2013;20:47–51. doi: 10.1155/2013/248167. [PMC free article] [PubMed] [Cross Ref]
23. Upham JW, James AL. Remission of asthma: the next therapeutic frontier? Pharmacol Ther. 2011;130:38–45. doi: 10.1016/j.pharmthera.2011.01.002. [PubMed] [Cross Ref]

Articles from Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology are provided here courtesy of BioMed Central